LungLifeAI Logo

Shareholder Information

Notice of Special Meeting

View Special Meeting Documentation

Other Exchanges and Trading Platforms

LungLife AI has not applied or agreed to have any of its securities admitted or traded on any other exchanges or trading platforms.

Shares in Issue

Number of AIM securities in issue: 30,658,603 shares are issued, called up and fully paid. The Company holds no shares in treasury. This figure should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

Significant Shareholdings

Significant shareholdersNo of Common Shares% of share capital
Simon Raab4,148,29313.5
Unicorn Asset Management3,907,14212.7
Lombard Odier Asset Management2,911,2209.5
Icahn School of Medicine at Mount Sinai2,469,8428.0
Octopus Investments1,968,7506.4
Stifel Nicolaus & Co.1,780,1475.8
Frederick Gluck1,757,3535.7
SYNO Ventures Master Fund LP1,377,3254.5
Livzon Pharmaceutical Group Inc1,347,6534.4
Investec Wealth & Investment1,222,6793.9
Accord Data Holdings954,0483.1

Director Shareholdings

DirectorNo of Common Shares% of share capital
Roy Davis28,5710.09
Andy Boteler19,9660.07
Paul Pagano26,4080.09
David Anderson26,4080.09

Shares Not in Public Hands

Percentage of securities not in public hands: As of 31 May 2024 the percentage of common shares not in the public hands was 49.4%.

Restrictions in Transfer of AIM Securities

There are no restrictions on the transfer of the Company’s common shares.

UK City Code on Takeovers and Mergers

LungLife AI is not subject to the City Code because its registered office is outside the UK, the Channel Islands and the Isle of Man. As a result, certain of the protections that are afforded to shareholders under the City Code, for example in relation to a takeover of a company or certain stakebuilding activities by shareholders, do not apply to LungLife AI. Certain provisions have been inserted into LungLife AI’s Certificate of Incorporation that adopt similar procedures to the City Code in the event of any party (or parties acting in concert) obtaining 30 per cent or more of the voting rights attaching to the issued Ordinary Shares, but there is no assurance that the courts of Delaware will uphold or allow the enforcement of these provisions.

This page was last updated on: 20 June 2024

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.